New director appointed to the Office for Human Research Protections (OHRP).
HHS Assistant Secretary for Health Joxel García, M.D., M.B.A., today announced the appointment of Jerry A. Menikoff, M.D., J.D, as the director of the Office for Human Research Protections (OHRP), part of the Office of Public Health and Science, in the Office of the Secretary.
Prior to joining OHRP, Dr. Menikoff served as the director of the Office of Human Subjects Research and a bioethicist, both at the National Institutes of Health. He has written extensively on research and human subject protections, including several books and numerous journal articles, over the past fifteen years.
Previous to his NIH appointments, Dr. Menikoff served for nine years as the chair of the human subjects committee and the hospital ethics committee at the University of Kansas Medical Center. His educational background includes an M.D. from Washington University and law and public policy degrees from Harvard. In addition, Dr. Menikoff has held academic positions in schools of law at the University of Akron, the University of Chicago, and Hofstra University, Hempstead, NY. He is on leave from the position of associate professor of law, ethics and medicine at the University of Kansas.
Dr. Ivor Pritchard, who had served as OHRP’s acting director since September 2007, will return to his position as senior advisor to the OHRP director.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.